Last reviewed · How we verify

hepcortespenlisimut-L — Competitive Intelligence Brief

hepcortespenlisimut-L (hepcortespenlisimut-L) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron metabolism regulator. Area: Hematology.

phase 3 Iron metabolism regulator Hepcidin Hematology Biologic Live · refreshed every 30 min

Target snapshot

hepcortespenlisimut-L (hepcortespenlisimut-L) — Immunitor LLC. Hepcortespenlisimut-L is a recombinant human prohepcidin analog that stimulates the production of hepcidin, a hormone that regulates iron metabolism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
hepcortespenlisimut-L TARGET hepcortespenlisimut-L Immunitor LLC phase 3 Iron metabolism regulator Hepcidin
DISC-1459 DISC-1459 Disc Medicine, Inc phase 3 Hepcidin mimetic Ferroportin (iron exporter); hepcidin pathway agonist

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron metabolism regulator class)

  1. Immunitor LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). hepcortespenlisimut-L — Competitive Intelligence Brief. https://druglandscape.com/ci/hepcortespenlisimut-l. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: